
Sunil Badve
@badves
Nephrologist, Conjoint Professor of Medicine @UNSWMedicine @georgeinstitute. 'Science is a way of thinking much more than it is a body of knowledge.' Carl Sagan
ID: 940672430
11-11-2012 06:22:25
3,3K Tweet
1,1K Takipçi
856 Takip Edilen


In this subanalysis of the #FLOW #RCT presented by Dr Katherine Tuttle at #AHA24, the benefit of #semaglutide in #diabetes w #CKD extended to patients with #CVD Listen to her insights on “the convergence of truth” to “save kidneys, hearts, & lives” #CKM #GLP1RA #DKD


Diabetes and obesity drugs have been found to reduce the risk of kidney failure and protect cardiovascular health in people with and without diabetes. New research by Sunil Badve and Vlado Perkovic published today 👇 bit.ly/3AUAKXB


Popular diabetes drugs like Ozempic can reduce the risk of kidney failure and death due to kidney or cardiovascular causes in people with and without diabetes, new research from Sunil Badve and Vlado Perkovic shows. The George Institute for Global Health bit.ly/3Zru4K4


Clear reductions in all outcomes with GLP-1RA: Kidney failure ✅ Major CV events ✅ Heart failure ✅ CV death ✅ All-cause death ✅ Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes Now in The Lancet Diabetes & Endocrinology thelancet.com/journals/landi…


📢 #GLP1 receptor agonists improve both kidney- and heart-related clinical outcomes for individuals with: ▶️ #type2diabetes ▶️ #chronickidneydisease ▶️ #overweight and #obesity Nephrology News & Issues Cardiology Today The Lancet Diabetes & Endocrinology Sunil Badve The George Institute for Global Health healio.com/news/endocrino…

#ICYMI: GLP-1 RA with and without SGLT2i Muthu Vaduganathan Sunil Badve Richard Pratley MD @lheath Brendon Neuen



Lauren R. Sorce Sebastian Palmqvist Niklas Mattsson-Carlgren Jan De Waele MD Toby Maher Alex Spyropoulos Most Viewed JAMA 2024: Medications for Obesity 🔗 ja.ma/3Djs3ab Dr Robert Kushner



Cardiovascular, Kidney & Mortality Outcomes With Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial by Matthew MY Lee et al. ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD ⬇️ 12% all-cause mortality diabetesjournals.org/care/article/d…


